API | syrosingopine

syrosingopine Report issue

Small molecule Experimental

ChEMBL Drug Central KEGG PubChem

Active Ingredient History

Syrosingopine, a drug derived from reserpine, which was investigated for the treatment of essential hypertension. The combination of syrosingopine and a mitochondrial inhibitor for the treatment of cancer and for achieving immunosuppression was patented. This invention also relates to a fluorescence-based method for predicting syrosingopine sensitivity of a cancer cell. ^NCATS

Chemistry

SMILES: CCOC(=O)OC1=C(OC)C=C(C=C1OC)C(=O)O[C@@H]2C[C@@H]3CN4CCC5=C(NC6=C5C=CC(OC)=C6)[C@H]4C[C@@H]3[C@@H]([C@H]2OC)C(=O)OC
InChIKey: ZCDNRPPFBQDQHR-SSYATKPKSA-N
Mol. Mass: 666.7148
ALogP: 4.7 Partition coefficient
ChEMBL Molecule:
syrosingopine

More Chemistry

Pharmacology

Mechanisms of Action: Missing data
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

methyl carbethoxysyringoyl reserpate | singoserp | syringopine | syrosingopin | syrosingopine

Indications (2)

Approved Indications (1)

Hypertension

Experimental Indications - Clinical Trial Phases 1-4 (1)

Neoplasms ()

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue